Drugs / CLINDE
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00612872 | Jan 2008 → Nov 2009 | Alzheimer disease, Parkinson disease, multiple sclerosis | Institute for Neurodegenerative Disorders | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CLINDE | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00612872 ↗ |
| Known as | [123I]CLINDE | “Drug: [123I]CLINDE” NCT00612872 ↗ |
| Modality | Diagnostic / imaging agent | “When labeled with 123-I and used as a SPECT radiotracer, CLINDE may serve as an in vivo marker of microglial activation in Alzheimer disease and Parkinson disease.” NCT00612872 ↗ |